Nvidia-Backed AI Drugmaker Iambic Raises $150 Million in US IPO
Deals·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Iambic Therapeutics Inc., a clinical-stage cancer drugmaker and technology firm, raised $150 million in a US initial public offering that priced at the midpoint of its marketed range.
The successful IPO highlights the growing interest in biotech firms leveraging artificial intelligence for drug development.
Iambic TherapeuticsNvidia
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Iambic Therapeutics Inc., a clinical-stage cancer drugmaker and technology firm, raised $150 million in a US initial public offering that priced at the midpoint of its marketed range.”
Bloomberg — Nvidia-Backed AI Drugmaker Iambic Raises $150 Million in US IPO